Randall Moreadith - Mar 26, 2024 Form 3 Insider Report for AgeX Therapeutics, Inc. (SER)

Role: Chief Scientific Officer
Signature: /s/ Randall Moreadith
Stock symbol: SER
Transactions as of: Mar 26, 2024
Transactions value $: $0
Form type: 3
Date filed: 4/3/2024, 08:07 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SER	Stock Option (right to buy)							Mar 26, 2024	Common Stock	521K	$0.06	Direct	F1, F2
holding	SER	Stock Option (right to buy)							Mar 26, 2024	Common Stock	93.8K	$0.06	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of capital stock of the corporation then known as Serina Therapeutics, Inc. ("Serina AL") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023, by and among the Issuer, Canaria Transaction Corporation and Serina AL (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of capital stock was exchanged for 0.97682654 shares of the Issuer's common stock, giving effect to a reverse split of the Issuer's common stock of 1-for-35.17.
F2	The stock options are fully vested.

Content

Shares of capital stock of the corporation then known as Serina Therapeutics, Inc. ("Serina AL") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023, by and among the Issuer, Canaria Transaction Corporation and Serina AL (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of capital stock was exchanged for 0.97682654 shares of the Issuer's common stock, giving effect to a reverse split of the Issuer's common stock of 1-for-35.17.

The stock options are fully vested.